3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Mantle-Cell
6
Recurrence
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, B-Cell
2
Burkitt Lymphoma
2
Waldenstrom Macroglobulinemia
1
Lymphoma
1
Leukemia, Hairy Cell
1
Hematologic Neoplasms
1
Interventions
Rituximab
16
zanubrutinib
12
ibrutinib
9
venetoclax
8
Cyclophosphamide
8
pirtobrutinib
5
fludarabine phosphate
5
Whole-Body Irradiation
5
Sirolimus
5
Mycophenolic Acid
5
Bendamustine Hydrochloride
5
acalabrutinib
4
Peripheral Blood Stem Cell Transplantation
4
Dexamethasone
4
ixazomib
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Lenalidomide
3
Cyclosporine
3
Bortezomib
3
Biopsy
3
fludarabine
2
carfilzomib
2
Tacrolimus
2
Prednisone
2
Melphalan
2
Etoposide
2
Cyclosporins
2
Calcium Dobesilate
2
CT-P10
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Waldenstrom Macroglobulinemia
×
brexucabtagene autoleucel
×
1 year
×
Clear all
NCT05537766
2026-03-10
ZUMA-25
Gilead Sciences
Phase 2
Terminated
19 enrolled
28 charts